Advances in the Use of Anti-inflammatory Agents to Manage Chemotherapy-induced Oral and Gastrointestinal Mucositis

Author(s): Vaishnavi J. Mahendran, Andrea M. Stringer, Susan J. Semple, Yunmei Song, Sanjay Garg*.

Journal Name: Current Pharmaceutical Design

Volume 24 , Issue 14 , 2018

Become EABM
Become Reviewer

Abstract:

Mucositis is a side effect associated with the use of chemotherapy, and has a significant impact on the quality of life. Mucositis, by definition, refers to the inflammation of the mucosa and occurs throughout the alimentary tract from the mouth to anus. Nuclear Factor kappa B (NFκB) encompasses a family of transcription factors, which upregulate pro-inflammatory cytokines. These are recognized as key targets in developing therapeutic interventions for chemotherapy-induced mucositis, and cyclooxygenase (COX)-2 inhibition may also be beneficial in reducing the severity and duration. This review focuses on the pathobiology of chemotherapy-induced oral and gastrointestinal mucositis and recent research examining the role of agents with anti-inflammatory activity in treatment and prevention of the condition. We consider agents in clinical use as well as some others under current investigation including plant-derived and other natural medicines.

Keywords: Mucositis, chemotherapy, gastrointestinal, inflammation, anti-inflammatory, natural agents.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 24
ISSUE: 14
Year: 2018
Page: [1518 - 1532]
Pages: 15
DOI: 10.2174/1381612824666180409093918
Price: $58

Article Metrics

PDF: 24
HTML: 5
EPUB: 1
PRC: 1